← Back to Search

18F-MFBG Imaging for Neuroendocrine Cancer

Phase 1 & 2

Recruiting

Led By Neeta Pandit-Taskar, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing a new tracer to see how it behaves in the body, how it is removed, and how well it shows neuroendocrine tumors.

Who is the study for?

This trial is for patients with certain neuroendocrine tumors, such as paraganglioma and neuroblastoma, who are over 5 years old and can have a PET scan without sedation. They must show signs of the tumor on a specific type of scan (MIBG) and not have severe organ damage or other serious illnesses.Check my eligibility

What is being tested?

Researchers are testing a new imaging agent called 18F-MFBG to see how it distributes in the body, its elimination process, and if it's effective at showing neuroendocrine tumors on PET scans. Participants will undergo PET imaging and blood tests.See study design

What are the potential side effects?

Since this trial focuses on imaging rather than drug treatment, side effects may be minimal but could include discomfort from injection or reactions related to lying still during the PET scan procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

dosimetry of 18F MFBG

radioactivity

Secondary outcome measures

18 F-MFBG imaging PET/CT to target known sites of disease

Trial Design

1Treatment groups

Experimental Treatment

Group I: pts with primary or metastatic neuroendocrine tumorsExperimental Treatment3 Interventions

For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,556 Total Patients Enrolled

12 Trials studying Neuroendocrine Tumors

423 Patients Enrolled for Neuroendocrine Tumors

Neeta Pandit-Taskar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

9 Previous Clinical Trials

278 Total Patients Enrolled

Media Library

18F-MFBG (meta-fluoro benzylguanidine) Clinical Trial Eligibility Overview. Trial Name: NCT02348749 — Phase 1 & 2

Neuroendocrine Tumors Research Study Groups: pts with primary or metastatic neuroendocrine tumors

Neuroendocrine Tumors Clinical Trial 2023: 18F-MFBG (meta-fluoro benzylguanidine) Highlights & Side Effects. Trial Name: NCT02348749 — Phase 1 & 2

18F-MFBG (meta-fluoro benzylguanidine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02348749 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the approximate sample size of participants in this experiment?

"Affirmative. The information posted on clinicaltrials.gov indicates that this research endeavour is open to recruitment and has been since its initial posting date of January 1st 2015. As of now, 66 participants are sought at a single location."

Answered by AI

Is this trial actively seeking participants at the moment?

"This research endeavour is still open to patient recruitment, with the information on clinicaltrials.gov being last revised in March 2022 since its initial posting in January 2015."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

2015. "18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02348749.

All > Neuroendocrine Tumor